Torthaí cuardaigh - Douglas Bootle
- 1 - 3 toradh as 3 á dtaispeáint
-
1
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours de réir M. Campone, Vincent Lévy, Emmanuelle Bourbouloux, Dominique Berton Rigaud, Douglas Bootle, Catherine Dutreix, Uwe Zoellner, N. Shand, Fabien Calvo, Éric Raymond
Foilsithe / Cruthaithe 2009Artigo -
2
Alpelisib Plus Fulvestrant in <i>PIK3CA</i>-Altered and <i>PIK3CA</i>-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer de réir Dejan Juric, Filip Janků, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiß-Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo
Foilsithe / Cruthaithe 2018Artigo -
3
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study de réir Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Janků, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiß-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga
Foilsithe / Cruthaithe 2018Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Breast cancer
Cancer
Internal medicine
Medicine
Oncology
Gastroenterology
Adverse effect
Cancer research
Chemotherapy
Endometrial cancer
Estrogen receptor
Everolimus
Fulvestrant
Metastatic breast cancer
Nausea
Neutropenia
Paclitaxel
Pharmacokinetics
Pharmacology
Phases of clinical research
Response Evaluation Criteria in Solid Tumors
Taxane
Toxicity
Vomiting